Next-generation iPSC technologies: From transplantable organs to advanced CNS disease models

Jiwu Wang, Ph.D.
CEO of Allele Biotech

Speaker bio:

Founding CEO of Allele Biotech and President of the Scintillon Institute, he is an RNA molecular biologist advancing mRNA-based reprogramming and iPSC engineering. He develops high-potency transient mRNA tools, leads ARPA-H–funded stem cell and RNA engineering programs, and holds multiple Allele patents.

Talk title:

Building Transplantable Organs Cell by Cell: mRNA Strategies for Multi-Lineage iPSC Differentiation

Abstract

The regenerative medicine field has advanced through organoid and organ-specific differentiation technologies. However, generating diverse cellular materials beyond single target cell types remains a key challenge. Dr. Wang will introduce mRNA-based strategies to precisely control gene expression, enabling multi-lineage differentiation from iPSCs. This approach supports the scalable production of various cell types from a single iPSC line, providing a powerful platform for building functional tissues and advancing organ transplantation strategies.

Irene Munk Pedersen, Ph.D.
Associate Professor at Scintillon Institute

Speaker bio:

Dr. Pedersen develops innovative stem cell–based 3D brain-on-a-chip models. Her platforms integrate blood, blood–brain barrier (BBB), and CNS components, enabling robust CNS drug screening and advanced modeling of neurological diseases. These next-generation models offer transformative potential for understanding CNS biology and accelerating therapeutic discovery.

Talk title:

Establishing Next-Generation BBB/CNS Interphase Disease Models

Abstract

To address bottlenecks and knowledge gaps in neuroscience and drug development, advanced blood-brain barrier (BBB)/CNS interphase microfluidic models are being developed. These 3D brain-on-a-chip culture systems allow in-depth investigation of disease pathophysiology and serve as late-stage drug screening platforms for CNS therapeutics. Dr. Pedersen will discuss how these next-generation models improve translational relevance and therapeutic evaluation.

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.